GenScript Signs an Agreement with Selecxine to Develop Therapies for Immuno-Oncology

 GenScript Signs an Agreement with Selecxine to Develop Therapies for Immuno-Oncology

GenScript Signs an Agreement with Selecxine to Develop Therapies for Immuno-Oncology

Shots:

  • GenScript will be responsible for all pre-clinical pharmacy research and IND filling in Selecxine’s project which is based on cytokine-antibody complexes
  • The company provided development solutions in different hosts tailored to customers and provided the preparation and purification solutions for the final complex,; further the project will test and enhance the process development capability of GenScript CDMO team
  • SLC-3010 is a complex of IL-2 and anti-human IL-2 antibody (TCB2) that selectively stimulates the anti-tumor immune response and its efficacy for the removal of various types of tumor was thoroughly demonstrated through various in vitro and in vivo experiments  

Click here to read full press release/ article | Ref: PRNewswire | Image: Behance

Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on shiwani@pharmashots.com

Related post